• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific pours another $37 million into overseas R&D

Boston Scientific pours another $37 million into overseas R&D

August 9, 2011 By MassDevice staff

Boston Scientific

More news from the Emerald Isle as the Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland.

The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system.

The funding is partially supported by a grant from IDA Ireland, a quasi-public investment promotion agency, which also provided incentive for New York-based chemotherapy device maker Delcath Systems Inc.’s (NSDQ:DCTH) decision to plant its European headquarters in Galway, Ireland.

Osteoporosis therapy company Osteologix Holdings plc (PINK:OLGXF) moved its entire corporate headquarters to Ireland after exiting the U.S. stock market on promises made late last year, but IDA Ireland doesn’t appear to have provided any incentive in that case.

"I have repeatedly stated that if we are to create the jobs and growth we so badly need, we must relentlessly promote an innovation agenda," Irish Minister for jobs, enterprise and innovation Richard Bruton said in prepared remarks. " R&D investments by leading multinationals like Boston Scientific not only create high-value jobs, but also provide substantial spin-off benefits for Irish businesses, researchers and ultimately the economy."

Boston Scientific, which ranked 10th on the MassDevice Big 100 list of the world’s largest medical device companies, landed in Ireland in 1994 and is now one of the country’s largest employers, according to the release.

The company continues to expand its global footprint with plans to invest $150 million in commercial expansion in China in hopes of seeing a $500 million return by 2017.

Filed Under: News Well, Research & Development Tagged With: Boston Scientific, Cardiac Rhythm Management, Delcath Systems Inc., Osteologix

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy